Alignment Healthcare: Conservative Guidance, Solid EBITDA Trajectory, and Limited Regulatory Risk Support Buy Rating and $25 Target

TIPRANKS02-28

Analyst Ryan Langston of TD Cowen reiterated a Buy rating on Alignment Healthcare, retaining the price target of $25.00. Ryan Langston has given hi...

Source Link
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap
Leave a comment